PMID- 31199486
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20200424
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Jan 1
TI  - The relationship between patient acceptable symptom state and disease activity in 
      patients with psoriatic arthritis.
PG  - 69-76
LID - 10.1093/rheumatology/kez202 [doi]
AB  - OBJECTIVES: The Psoriatic Arthritis Disease Activity Score (PASDAS) and Disease 
      Activity Index for Psoriatic Arthritis (DAPSA) are composite PsA disease activity 
      measures. We sought to identify the PASDAS and DAPSA cut-off points consistent 
      with patient acceptable symptom state (PASS), the threshold of symptoms beyond 
      which patients consider themselves well, and examine PASS across published PASDAS 
      and DAPSA thresholds for low, moderate and high disease activity. METHODS: We 
      used a standard protocol including physician assessment and patient-reported 
      outcomes to prospectively record measures required to calculate PASDAS and DAPSA. 
      We identified PASS thresholds for the PASDAS and DAPSA using receiver operating 
      characteristics curve analyses. We assessed the frequency of reporting acceptable 
      symptom state across disease activity thresholds for PASDAS and DAPSA scores. 
      RESULTS: A total of 229 patients (58.5% male, mean age 55.5 years, mean disease 
      duration 17.1 years) were recruited. The PASS threshold for the PASDAS was 3.79 
      [area under the curve (AUC) 0.86, sensitivity 0.75, specificity 0.82] and for the 
      DAPSA was 11.10 (AUC 0.91, sensitivity 0.89, specificity 0.82). With the PASDAS, 
      90% of patients defined as having low disease activity considered their symptom 
      state acceptable, compared with 55% and 17% among those with moderate and high 
      disease activity, respectively. With the DAPSA, 98% of patients in disease 
      remission considered their symptom state acceptable compared with 85, 22 and 18% 
      among those with low, moderate and high disease activity, respectively. 
      CONCLUSION: We have defined PASS thresholds for PASDAS and DAPSA. The PASDAS 
      target for low disease activity and DAPSA targets of low disease activity or 
      remission align well with PASS.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Fei, Jeanie Z
AU  - Fei JZ
AD  - Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic 
      Diseases, Krembil Research Institute, University Health Network, Toronto, 
      Ontario, Canada.
AD  - Faculty of Medicine, Western University, London, Ontario, Canada.
FAU - Perruccio, Anthony V
AU  - Perruccio AV
AD  - Health Care & Outcomes Research and Arthritis Program, Krembil Research 
      Institute, University Health Network, Toronto, Ontario, Canada.
AD  - Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public 
      Health, University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Ye, Justine Y
AU  - Ye JY
AD  - Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic 
      Diseases, Krembil Research Institute, University Health Network, Toronto, 
      Ontario, Canada.
FAU - Gladman, Dafna D
AU  - Gladman DD
AD  - Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic 
      Diseases, Krembil Research Institute, University Health Network, Toronto, 
      Ontario, Canada.
AD  - Health Care & Outcomes Research and Arthritis Program, Krembil Research 
      Institute, University Health Network, Toronto, Ontario, Canada.
AD  - Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
FAU - Chandran, Vinod
AU  - Chandran V
AD  - Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic 
      Diseases, Krembil Research Institute, University Health Network, Toronto, 
      Ontario, Canada.
AD  - Health Care & Outcomes Research and Arthritis Program, Krembil Research 
      Institute, University Health Network, Toronto, Ontario, Canada.
AD  - Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
SB  - IM
CIN - Rheumatology (Oxford). 2020 Jan 1;59(1):1-4. PMID: 31504999
MH  - Area Under Curve
MH  - Arthritis, Psoriatic/*diagnosis
MH  - Female
MH  - *Health Status Indicators
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - *Patient Reported Outcome Measures
MH  - Prospective Studies
MH  - ROC Curve
MH  - Reference Values
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Symptom Assessment/methods/*statistics & numerical data
OTO - NOTNLM
OT  - outcome measure
OT  - psoriasis
OT  - spondyloarthritis
EDAT- 2019/06/15 06:00
MHDA- 2020/04/25 06:00
CRDT- 2019/06/15 06:00
PHST- 2019/01/10 00:00 [received]
PHST- 2019/04/23 00:00 [revised]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2019/06/15 06:00 [entrez]
AID - 5519078 [pii]
AID - 10.1093/rheumatology/kez202 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2020 Jan 1;59(1):69-76. doi: 10.1093/rheumatology/kez202.